title: Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
abstract: Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir. Foscarnet-resistant isolates with DNA polymerase mutations in regions II, VI, and between I and VII were also associated with an important decrease in susceptibility to adefovir (mean IC50 increase: 4.6-fold compared to pre-foscarnet or wild-type isolates) suggesting that adefovir-resistant HSV could be selected in vivo by foscarnet therapy.
authors.affiliation: Centre de Recherche en Infectiologie of the Centre Hospitalier Universitaire de Québec (Pavillon CHUL), and Universiteé Laval, Québec, Canada.
authors.forename: Julie
authors.initials: J
authors.lastname: Bestman-Smith
authors.forename: Guy
authors.initials: G
authors.lastname: Boivin
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000821:virology*; D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017245:Foscarnet / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D006558:Herpes Genitalis / Q000821:virology*; D006561:Herpes Simplex / Q000821:virology*; D018259:Herpesvirus 1, Human / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D018258:Herpesvirus 2, Human / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D017245:Foscarnet; C053001:adefovir; D000225:Adenine